AdiFectin™ (bis (phytanyl) N4-{N1-[(4-((6-amino-2-(butylamino)-8-hydroxy- 9H-purin- 9-yl) methyl) benzoyl) glycinyl] sperminyl} propyl phosphonate) is derived from CL307 by conjugation with a bis(phytanyl) phosphonate group.
Addition of this lipid confers to the molecule the ability to form positively charged liposomes, which can encapsulate DNA (or RNA). AdiFectin™ is a weaker TLR7 agonist than CL307, but in contrast to CL307, is able to efficiently complex nucleic acids resulting in a strong IFN response and transgene expression when the nucleic acid is a plasmid DNA carrying an expression cassette.
Repeated in vivo studies have showed that pDNA/AdiFectin™ complexes display robust anti-tumor activity . Tumor growth was markedly reduced resulting in a 50% survival rate. Notably, mice that achieved long-term clearance of tumor following AdiFectin™ treatment were protected from subsequent tumor rechallenge suggesting the generation of a tumor-specific memory immune response.
